Trial Profile
Safety and efficacy of transarterial chemoembolization (TACE) combined with apatinib (TACE-apatinib) in patients with Barcelona Clinic Liver Cancer (BCLC) stage C of hepatocellular carcinoma: A retrospective controlled study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Mar 2019
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 23 Feb 2018 New trial record
- 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium